Mar Rhino (Xylometazoline Hydrochloride)

Xylometazoline Hydrochloride is a selective alpha‑adrenergic agonist. By stimulating alpha‑1 receptors on the blood vessels of the nasal mucosa, it causes vasoconstriction, which reduces blood flow, decreases mucosal edema, and opens the nasal airway, providing rapid decongestion.

The prescribed dose is determined by the treating clinician. Typically, adults may use one to two sprays per nostril, up to three times daily, while children follow the dosage recommended on the product label or by a healthcare professional.

Safety data for Xylometazoline Hydrochloride during pregnancy and lactation are limited. Women who are pregnant, planning pregnancy, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using Mar Rhino.

To place an order, submit an enquiry on the Mar Rhino product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mar Rhino contains Xylometazoline, an imidazoline‑type decongestant, which typically provides rapid relief with a lower risk of systemic side effects compared with phenylephrine‑based products. However, all topical decongestants share a similar risk of rebound congestion if used beyond the recommended duration.

Store Mar Rhino at room temperature, below 25 °C, in its original packaging. Protect the bottle from moisture, extreme heat and direct sunlight. Keep the spray tip clean and replace the cap securely after each use.

Mar Rhino is administered as a nasal spray. The user tilts the head slightly forward, inserts the nozzle into one nostril, closes the opposite nostril, and sprays the prescribed number of actuations while breathing in gently. Repeat in the other nostril if directed.

Serious risks include severe hypertension, tachycardia, significant nosebleeds, allergic reactions such as rash or anaphylaxis, and rebound congestion (rhinitis medicamentosa) after prolonged use. Any sudden increase in blood pressure, persistent bleeding, or signs of an allergic response should prompt immediate medical attention.

Mar Rhino should be avoided in children under 6 years of age unless a physician advises otherwise, in individuals with known hypersensitivity to Xylometazoline or any formulation component, and in patients with severe uncontrolled hypertension or recent nasal surgery without medical guidance.